Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 22, 2010

GeneGo’s Pathway Analysis Platform Coupled with Agilent’s Informatics Solution

  • GeneGo has integrated Agilent Technologies' GeneSpring Bioinformatics Solution with its pathway analysis technology, MetaCore.GeneSpring GX 11.5, released today, is a multiomics microarray and mass spectrometry based analysis suite that handles transcriptomics, genomics, metabolomics, and proteomics data in one application.

    GeneSpring now includes a direct connection to MetaCore that allows users to upload expression data analyzed in GeneSpring for pathway analysis in MetaCore. "Our users have access to analysis and visualization tools within GeneSpring and the ability to combine statistical analysis in GeneSpring with MetaCore's strengths in pathway analysis," says Michael Janis, GeneSpring product manager at Agilent.

    MetaCore 6.3 assists scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states, and toxicology. "MetaCore can concurrently visualize multiple types of data and will be able to take advantage of this new functionality in GeneSpring, which will be very helpful to our joint customers," says Julie Bryant vp of business development at GeneGo.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »